W. Pan
AstraZeneca (Brazil)(BR)Alexion Pharma (Switzerland)(CH)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, Monoclonal and Polyclonal Antibodies Research, Biosimilars and Bioanalytical Methods, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC(2021)52 cited
- → LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study(2023)41 cited
- → Cocaine and alcohol interactions in naive and alcohol-pretreated rats.(1996)35 cited
- → Preclinical development ofAMG139, a human antibody specifically targetingIL‐23(2014)31 cited
- → A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24‐h intragastric pH(2001)23 cited
- → 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522(2022)6 cited
- → 99P Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States(2022)3 cited
- → 186P Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy(2022)3 cited
- → P008 Pharmacokinetics and pharmacodynamics in cynomolgus monkeys of AMG 181, a fully human anti α4 β7 antibody for treating inflammatory bowel disease(2012)3 cited
- → 191MO KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs(2023)2 cited